POULPHARM
ActiveSummary
POULPHARM has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.2m and a net result of €456,285. Equity has been growing by about 25% per year since 2018. Its solvency ranks better than 22% of 239 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
Overview
Official details
Source: KBO- Status
- Active since 27-03-2007 Normal situation
- Activity
- Research and development on biotechnology NACE 72101and 1 other
- Joint committee
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 2025
- Establishment units
- 2.162.609.456 8870 Izegem, since 13-03-2007
- 2.217.357.642 8551 Zwevegem, since 01-11-2012and 3 others
- Financial year end
- 31 December
- Peppol
- Reachable since 20-11-2020
Board and ownership
- DE SASMEESTERDirector · permanent representative Joris Pieter DE GUSSEM
- Auditor
- AUDITAS BEDRIJFSREVISOREN
- De Sasmeester CommVconsolidatesannual accounts 2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.1%
- Turnover
- €17.0m
- ▲ 3.9%
- Profit
- €456,285
- ▼ 73.6%
- Equity
- €2.2m
- ▲ 26.7%
- Total assets
- €15.5m
- ▼ 0.5%
- Employees on 31-12-2025
- 115
- ▲ 12.7%
- 2025 accounts filed 28 days after the deadline
Score breakdownraises riskLiquidity: current ratio 0.83, cash €242,510Equity €2.2m (14.0% of total assets)1 change of registered office in 24 monthslowers riskSector: Scientific research and development (NACE 72)Show the evidence
Checked score
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, medium-sized). It does better than 30% of them on solvency, 21% on liquidity, 55% on profitability and 75% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 17 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Registered office moved within IzegemPermanent representative: Joris Pieter De Gussem
- · Gazette deed Appointment: Auditas Bedrijfsrevisoren (statutory auditor)Permanent representative: Sven Vansteelant
- · Gazette deed Company renamed from POULPHARM BVBA to POULPHARMChange of role: DE SASMEESTER, from manager to director · Permanent representative: Joris Pieter DE GUSSEM
Comparable companies
These companies have the same main activity as POULPHARM: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €8.5m and €29m, founded between 2003 and 2014.
| Company | Total assets | Turnover |
|---|---|---|
| POULPHARM Izegem | €15.5m | €17.0m |
| DIAGENODE Seraing | €21.1m | €11.9m |
| SYNEOS HEALTH BELGIUM Brussel | €8.5m | €18.9m |
| Enovalife Evere | €21.9m | €25.2m |
| LaCAR MDx technologies Liège | €29.1m | €8.1m |
| Inbiose Gent | €17.2m | €6.3m |
| Sartorius Xpress Biologics Herstal | €10.9m | €2.4m |
Key facts about POULPHARM
- What is the company number of POULPHARM?
- The company number of POULPHARM is 0888.282.250. The VAT number is the same number with BE in front: BE 0888.282.250.
- Where is POULPHARM based?
- The registered office is at Kokelarestraat 83, 8870 Izegem.Company details
- What does POULPHARM do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of POULPHARM?
- The legal form of POULPHARM is Private limited company (BV).
- When was POULPHARM founded?
- POULPHARM was founded on 27-03-2007.
- Is POULPHARM still active?
- Yes, POULPHARM is an active enterprise in the KBO register.
- How many employees does POULPHARM have?
- POULPHARM had an average of 106 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does POULPHARM fall under?
- In its 2025 annual accounts, POULPHARM states joint committee 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of POULPHARM?
- The turnover of POULPHARM was €17.0m in financial year 2025, according to the filed annual accounts.
- Is POULPHARM profitable?
- In financial year 2025, POULPHARM made a profit of €456,285.
- Where can I find the annual accounts of POULPHARM?
- POULPHARM filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of POULPHARM due?
- POULPHARM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.